BioSpace News Archive

In many situations, heart muscle cells do not respond to external stresses in the same ways that skeletal muscle cells do.

GT Biopharma, Inc. today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa’s Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD).

Artio Medical, Inc. today announces the appointment of Abhinav Shukla to the company’s Board of Directors.

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International, announced the regulatory approval for Tucidinostat monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma by the Japanese Pharmaceuticals and Medical Devices Agency.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has accepted the Company’s New Drug Application for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Carmot Therapeutics, Inc. announced today the initiation of the phase 1 study for CT-388, a once weekly, fully biased dual GLP-1 and GIP receptor modulator, in otherwise healthy overweight and obese participants.

Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

Appili Therapeutics Inc. today announced its financial and operational results for the fiscal year ended March 31, 2021, and provided an update on the Company’s strategy for fiscal 2022.

New Science 37 ® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize